Peptide Research Profile

AOD-9604

hGH Fragment 177-191 (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe) — Lipolytic GH Fragment

Evidence Grade: Phase 3 Failed · Development Discontinued

A modified 16-amino-acid fragment corresponding to the C-terminal region (amino acids 177–191) of human growth hormone, with an additional tyrosine at the N-terminus. Developed by Metabolic Pharmaceuticals (Melbourne, Australia) based on the hypothesis that GH’s lipolytic activity resides in this C-terminal region and can be isolated from GH’s growth-promoting (IGF-1-mediated) effects. AOD-9604 reached Phase 3 clinical trials for obesity but failed to demonstrate efficacy. Clinical development was discontinued. Despite this failure, AOD-9604 remains popular in the peptide community, particularly for body fat reduction claims.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. AOD-9604 FAILED its Phase 3 clinical trial for obesity and development was discontinued. It has no approved indication anywhere in the world. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

hGH Fragment

16 amino acids — GH C-terminal fragment (177-191) with N-terminal tyrosine

Developer

Metabolic Pharmaceuticals

Melbourne, Australia — developed through Phase 3, then discontinued

Evidence Level

Phase 3 Failed

Phase 3 RCT did NOT meet primary endpoint for obesity • Development abandoned

Key Pathway

Beta-3 Adrenergic?

Proposed β3-AR-mediated lipolysis without IGF-1 elevation — mechanism poorly characterized

Pharmacology

Mechanism of action

AOD-9604’s mechanism of action is, frankly, poorly characterized compared to most peptides on this site. The original hypothesis was that the C-terminal region of GH (residues 177–191) contains an independent lipolytic domain that does not require the GH receptor or JAK2/STAT5 signaling. Instead, AOD-9604 was proposed to stimulate lipolysis through beta-3 adrenergic receptor-mediated pathways in adipose tissue, without elevating IGF-1 or producing GH-like growth effects. While preclinical data supported this concept, the Phase 3 failure in humans calls the entire mechanistic framework into question.

Subcutaneous or Oral Administration

AOD-9604 was studied via both subcutaneous injection and oral administration (unusual for a peptide). The oral formulation was the primary route in the Phase 3 trial, using a relatively high dose (1 mg/day oral). Oral bioavailability of a 16-amino-acid peptide is expected to be very low, but the disulfide bond between the two cysteines (Cys182 and Cys189) may confer some resistance to gastric proteolysis. Nonetheless, the oral bioavailability was likely <5%.

Oral peptide challenge: The oral formulation was developed as a commercial advantage — an oral fat-loss pill would be far more marketable than an injectable peptide. The 1 mg oral dose likely delivered only micrograms of intact peptide to systemic circulation. The Phase 3 failure may be partly a bioavailability problem rather than a target validity problem — or it may be that the target itself (GH-independent lipolysis via a GH fragment) is not valid in humans. This distinction matters for interpretation but was never resolved because development was abandoned.

Proposed: GH-Independent Lipolytic Pathway

The core hypothesis is that AOD-9604 stimulates lipolysis through a mechanism independent of the canonical GH receptor (GHR). In vitro studies showed AOD-9604 activated lipolysis in adipose tissue explants without activating JAK2/STAT5 (the GHR signaling pathway) and without increasing IGF-1. The proposed mechanism involves beta-3 adrenergic receptor (ADRB3) sensitization and direct activation of hormone-sensitive lipase (HSL) through a non-GHR pathway.

Evidence for and against: Early in vitro work (Ng & Borstein, 2000) showed AOD-9604 stimulated lipolysis in rat fat pads with potency comparable to full-length GH, without displacing GH from its receptor. This suggested a separate binding site or mechanism. However, the specific receptor for AOD-9604 was never identified. The beta-3 adrenergic receptor involvement was inferred from indirect evidence (beta-3 antagonist blocking the effect in rodent models) but not confirmed by direct binding studies. The ADRB3 mechanism is especially problematic because human beta-3 receptors are far less functional in adipose tissue than rodent beta-3 receptors — a well-known species difference that has derailed multiple drug candidates.

Proposed: Anti-Lipogenic Effect

Beyond lipolysis, AOD-9604 was proposed to have anti-lipogenic effects — inhibiting the formation of new fat. In cell culture, AOD-9604 reduced incorporation of radiolabeled acetate into fatty acids, suggesting inhibition of de novo lipogenesis (DNL). This anti-lipogenic activity was additive to the lipolytic activity, theoretically producing both fat burning and fat storage prevention simultaneously.

DNL inhibition mechanism: The proposed pathway involved reduced expression of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) in adipocytes treated with AOD-9604. However, these findings were from cell culture at micromolar concentrations that may not be achievable systemically with oral or subcutaneous dosing. The anti-lipogenic claims were never validated in human tissue or in vivo with measurable body composition outcomes. The in vitro to in vivo translation gap is substantial.

No IGF-1 Elevation (The Selling Point)

AOD-9604’s primary marketing distinction was that it does not elevate IGF-1. Full-length GH produces lipolysis but also stimulates IGF-1 production, which promotes cell growth (potential cancer concern), insulin resistance, and acromegalic features at high doses. By isolating the lipolytic fragment from the IGF-1-stimulating domain, AOD-9604 was positioned as “the fat-burning benefits of GH without the risks.” This was confirmed in Phase 1/2 studies — no IGF-1 elevation was observed.

Why no IGF-1: IGF-1 production requires GH receptor activation and JAK2/STAT5 signaling in hepatocytes. The GH receptor binding domain is located in the N-terminal region (Site 1: residues 10–33) and the central region (Site 2: residues 54–74). The C-terminal fragment (177–191) does not contain either binding site. Therefore, AOD-9604 physically cannot activate the GH receptor or stimulate IGF-1. This is confirmed pharmacologically — the peptide is a GH fragment that lacks the receptor-binding epitopes.

Phase 3 Failure: The Central Problem

In a Phase 3, 24-week, randomized, double-blind, placebo-controlled trial in obese adults (n=536), oral AOD-9604 at 1 mg/day did not produce statistically significant weight loss compared to placebo. The trial was conducted by Metabolic Pharmaceuticals in collaboration with Monash University. After this failure, the company abandoned further development. This is the most important fact about AOD-9604 and should inform all subsequent claims about its efficacy.

Trial details: The Phase 3 trial randomized 536 obese adults (BMI 35–45) to oral AOD-9604 (1 mg/day) or placebo for 24 weeks, with diet and exercise counseling for all participants. Primary endpoint: mean change in body weight. Result: ~2.8 kg weight loss in both the AOD-9604 and placebo groups — no significant difference (p>0.05). The diet/exercise counseling produced identical results in both groups, and AOD-9604 added nothing. Secondary endpoints (waist circumference, body fat percentage by BIA) also showed no benefit. The trial was adequately powered and well-conducted — this is a clean negative result, not an underpowered or flawed study.

Administration

Delivery routes

Oral

Route Used in Phase 3 (Failed)

The oral route was the primary development focus due to commercial appeal. The Phase 3 trial used 1 mg/day oral dosing. Despite the inherent bioavailability challenges of oral peptides, this route was chosen for marketability. The Phase 3 failure may reflect poor oral bioavailability, lack of target validity, or both.

Subcutaneous Injection

Community Use

Subcutaneous injection (typically 250–300 mcg/day) is the preferred route in the peptide community, based on the assumption that poor oral bioavailability contributed to the Phase 3 failure. This is a plausible hypothesis but unproven — no Phase 3 trial of SC AOD-9604 has been conducted. SC dosing may produce higher systemic levels, but there is no evidence this translates to clinical efficacy.

Intraperitoneal (Rodent)

Research Only

Rodent studies showing efficacy used IP injection, which provides high systemic bioavailability. The positive preclinical results with IP dosing combined with the Phase 3 oral failure suggests the route of administration matters, but this has never been resolved with a human SC trial.

Topical / Transdermal

Not Viable

A 16-amino-acid peptide cannot penetrate intact skin in meaningful quantities. No transdermal or topical AOD-9604 product has been studied. Any product claiming topical AOD-9604 fat reduction is not supported by any evidence.

Protocols

Dosing reference

Dosing data comes from the failed Phase 3 oral trial and community subcutaneous protocols. The fundamental efficacy of AOD-9604 at any dose via any route in humans has not been established.

Context	Dose	Frequency	Source
Phase 3 obesity trial (FAILED)	1 mg/day oral Did NOT beat placebo for weight loss	Once daily for 24 weeks	Metabolic Pharmaceuticals Phase 3
Phase 2 dose-ranging	1–25 mg/day oral Higher doses also did not show clear efficacy	Once daily for 12 weeks	Metabolic Pharmaceuticals Phase 2
Subcutaneous (community)	250–300 mcg/day SC No clinical trial supports this route/dose	Daily for 4–12 weeks	Community protocols / anecdotal
Rodent efficacy dose	500 mcg/kg IP ~35 mg for a 70 kg human — much higher than community doses	Daily for 14–21 days	Ng & Borstein, 2000

Important: AOD-9604 FAILED its Phase 3 trial at 1 mg/day oral dosing. There is no established efficacious dose in humans for any route of administration. Community SC dosing protocols are based on hope and extrapolation, not clinical evidence. The peptide community’s assumption that SC administration would succeed where oral failed is a plausible but unproven hypothesis.

Outcomes

Benefits & side effects

Reported Benefits

No IGF-1 Elevation (Confirmed)

Phase 1 and Phase 2 studies confirmed that AOD-9604 does not elevate IGF-1, distinguishing it from full-length GH. This means no IGF-1-mediated cancer risk, no insulin resistance from IGF-1 signaling, and no acromegalic features. This is the most robustly confirmed property of AOD-9604.

Phase 1/2 human data • Confirmed

Safety Profile Appears Clean

Across Phase 1, 2, and 3 trials, AOD-9604 showed no significant adverse events compared to placebo. The safety data is actually quite strong for a peptide — over 500 subjects were exposed in controlled trials with no safety signals. It is safe. It simply doesn’t appear to work for weight loss.

Phase 1/2/3 safety data • n=500+ • Clean safety profile

Preclinical Lipolysis (Rodent)

In rodent models, AOD-9604 reduced body fat, stimulated lipolysis, and inhibited lipogenesis. These effects were reproducible across several studies from the Monash University group. The preclinical data was genuinely promising — which is why it progressed to Phase 3. The problem was human translation.

Rodent IP studies • Monash University group

TGA Approval for Osteoarthritis (Australia)

In 2020, the Australian TGA approved an intra-articular AOD-9604 product for osteoarthritis (knee). This is a different application (joint injection, not systemic fat loss) based on purported cartilage-protective properties. The osteoarthritis data is limited and the approval was through the TGA’s low-evidence pathway for complementary medicines.

Australian TGA approval • Intra-articular use only • Limited evidence basis

Adverse Effects & Risks

No Significant AEs (Clinical Data)

Phase 1, 2, and 3 trials showed no statistically significant difference in adverse event rates between AOD-9604 and placebo. The most common reports were headache, nausea, and upper respiratory infection — all at rates similar to placebo. This is perhaps the most thoroughly safety-tested peptide on this page.

Phase 1/2/3 • n=500+ across trials • Clean safety profile

Inefficacy as a Risk

The primary “risk” of AOD-9604 is financial — spending money on a peptide that failed its definitive clinical trial. Users who delay evidence-based weight management interventions in favor of AOD-9604 may experience opportunity cost to their health outcomes.

Phase 3 failure • Opportunity cost concern

Unknown SC Route Safety

While the oral route has extensive safety data, the subcutaneous route used by the community has no safety data beyond the general observation that SC injection of small peptides is generally well-tolerated. Any unique toxicity of SC AOD-9604 would be unknown.

Absence of SC-specific safety data

Quality Assurance Concerns

Gray-market AOD-9604 may contain impurities, degradation products, or entirely different compounds. The disulfide bond between Cys182 and Cys189 is susceptible to oxidation and scrambling during storage, potentially producing inactive or altered products.

Supply chain concern • Disulfide stability issue

Evidence Base

Key studies

Phase 3 Randomized Controlled Trial (FAILED)

AOD-9604 for Obesity: Phase 3 Trial

Metabolic Pharmaceuticals / Monash University • 2007 • n=536

Design & Findings

24-week, double-blind, placebo-controlled trial. Oral AOD-9604 (1 mg/day) in obese adults (BMI 35–45). Primary endpoint: change in body weight. RESULT: No statistically significant difference between AOD-9604 and placebo. Both groups lost approximately 2.8 kg (attributable to diet/exercise counseling). Secondary endpoints (waist circumference, body composition) also negative.

Significance

This is the definitive trial. It was adequately powered, well-conducted, and produced a clean negative result. This failure led Metabolic Pharmaceuticals to abandon AOD-9604 development for obesity entirely. Any current claims about AOD-9604’s fat-loss efficacy must be evaluated against this Phase 3 failure.

Limitations

Oral route only — SC was not tested. The 1 mg oral dose may have provided insufficient systemic exposure due to poor bioavailability. However, Phase 2 tested doses up to 25 mg oral with similarly negative results, weakening the bioavailability argument.

View on PubMed

Preclinical — Mechanism

hGH Fragment 177-191 Stimulates Lipolysis in Adipose Tissue

Ng FM, Borstein J • Endocrinology • 2000 • In vitro + Rodent

Design & Findings

The C-terminal fragment of hGH (177-191, modified with N-terminal Tyr) stimulated lipolysis in rat adipose tissue explants at potency comparable to full-length GH. The effect was not blocked by GH receptor antagonists but was blocked by beta-3 adrenergic antagonists. No IGF-1 elevation. Chronic IP dosing in ob/ob mice reduced body weight.

Significance

The foundational preclinical paper that launched AOD-9604 development. Established the hypothesis that GH’s lipolytic activity can be isolated from its growth-promoting activity. The rodent data was genuinely compelling.

Limitations

In vitro and rodent data only. The beta-3 receptor mechanism has a known species-translation problem (human ADRB3 is less functional in white adipose tissue than rodent ADRB3). ob/ob mice are a severe genetic obesity model that may not predict human responses.

View on PubMed

Phase 2 — Dose Ranging

Phase 2 Study of Oral AOD-9604 in Obese Adults

Metabolic Pharmaceuticals • 2004 • n=300

Design & Findings

12-week, multi-dose trial testing oral AOD-9604 at 1, 5, 10, and 25 mg/day. The 1 mg dose showed the most favorable trend (though not statistically significant), which led to its selection for Phase 3. Higher doses did not show better efficacy, suggesting the issue was not dose-dependent within the oral range tested.

Significance

The lack of dose-response is concerning — effective drugs typically show dose-dependent efficacy. The selection of 1 mg for Phase 3 based on a non-significant trend was optimistic. The flat dose-response across 1–25 mg oral range argues against the bioavailability explanation for Phase 3 failure.

Limitations

Phase 2 with shorter duration (12 weeks). The absence of dose-response undermines the mechanism. Published data is limited — full results were presented at conferences but not published in a peer-reviewed journal.

View on PubMed

Open Questions

Research gaps

Phase 3 Failure Is the Elephant in the Room

AOD-9604 FAILED its Phase 3 trial for obesity. This is not a peptide that simply “hasn’t been tested yet” — it has been tested in the most rigorous way possible and found ineffective. Community enthusiasm for AOD-9604 exists in spite of, not because of, the clinical evidence. The burden of proof for resurrection of this compound is very high.

SC Route Never Tested in Phase 3

The community argument is that oral bioavailability was the problem and SC injection would work better. This is plausible but unproven. No sponsor has funded an SC Phase 3 trial because the Phase 3 oral failure made the compound commercially unattractive. Without an SC trial, this remains speculation.

Mechanism Poorly Defined

The specific receptor for AOD-9604 was never identified. The beta-3 adrenergic involvement is inferred from indirect evidence. The distinction between in vitro lipolysis in rat fat pads and clinical weight loss in humans was never bridged. We don’t actually know how (or if) AOD-9604 works in human adipose tissue.

No Body Composition Data (Even Negative)

The Phase 3 trial used total body weight as the primary endpoint. Interestingly, no DEXA or MRI body composition data was published. If AOD-9604 stimulates lipolysis but the fat is replaced by water or lean tissue, total weight might not change even with fat loss. This alternative explanation has been proposed but is speculative.

Species Translation Problem

The rodent efficacy data may reflect a genuine species difference: rodent white adipose tissue has functional beta-3 adrenergic receptors that robustly drive lipolysis, while human white adipose tissue has very low ADRB3 expression and minimal lipolytic response to ADRB3 agonism. Multiple ADRB3 agonist drugs (CL-316,243, mirabegron for fat loss) have also failed to translate from rodent to human.

Opportunity Cost for Users

Community members using AOD-9604 for fat loss are spending time and money on a compound with a Phase 3 failure, when FDA-approved alternatives exist (semaglutide, tirzepatide) with robust efficacy data. The opportunity cost of using AOD-9604 instead of proven interventions is a genuine clinical concern.

Citations

References & further reading

1. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragment of human growth hormone. Endocrinology. 2000;141(4):1556-1562. PubMed

2. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment. Growth Horm IGF Res. 2001;11(6):398-407. PubMed

3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Growth Horm IGF Res. 2013;23(1-2):16-22. PubMed

4. Thompson D, Karpe F, Lafontan M, Frayn K. Physical activity and exercise in the regulation of human adipose tissue physiology. Physiol Rev. 2012;92(1):157-191. PubMed

5. Handelsman DJ, Gooren LJ. Hormones and sport: physiology, pharmacology, and forensic science. Asian J Androl. 2008;10(3):391-402. PubMed

All AOD-9604 on PubMed → ← Back to Research Library